The liquidity challenges reported on June 12 persist. Eevia has no access to new non-dilutive funding and is unable to execute equity issues, particularly rights issues. The restructuring plan is progressing well, and Eevia has a small revenue growth. Several new and significant sales contracts would support further growth, and Eevia is also in process on sales opportunities with several globally recognized blue-chip companies, which would fuel longer term revenue growth. Sales in the last few months from inventory have generated cash, and substantial cost reductions were implemented over the summer. Preparations for relocating production to a new facility are also advancing, promising a dramatic cut in future fixed operational expenses.

However, the average debt maturities remain short relative to the speed of converting current assets to cash. In other words, the cash flow from sales is insufficient to cover all obligations. Many creditors are pressing for payment, and the Company faces pressure to finalize repayment plans for certain statutory debts.

The Company’s financial position has triggered an evaluation of the assumption of the going concern principle, which has triggered an evaluation of the liquidation value of assets. This has delayed the audit process and the reporting of its 2024 statutory financial statements. In conclusion, the Company have agreed to significant write-downs to the estimated "market value" for its machinery, equipment, inventory and other asset classes. These adjustments—driven by accounting and audit requirements—do not necessarily reflect a loss of value under normal operations, but instead approximate realizable values in a liquidation scenario.

The write-downs will materially and negatively affect reported equity as of December 31, 2024, but are expected to enable the issuance of an unqualified audit opinion. Once the audit report is received, the Board will call a General Meeting and publish the 2024 statutory financial statements, currently expected on August 20, but still dependent on the receipt of the audit report.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com  or investor@eeviahealth.com                     

Telephone: +358 400 22 5967                         

This disclosure contains information that EEVIA HEALTH PLC must make public according to the EU Market Abuse Regulation (EU nr 596/2014). The information was initially submitted for publication through the contact person's agency on August 13, 2025, at 10:00 EST.

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc is a health ingredient company specialized in sustainable bioactive extracts from wild-harvested Nordic plants and berries. With a focus on gut health, kidney, and urinary health, as well as cellular protection, and inflammation, Eevia offers clinically relevant ingredients to global nutraceutical brands.

Eevia Health, founded in 2017, is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA. To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.